重症アトピー性皮膚炎 - 市場考察、疫学、市場予測（2034年）

主なハイライト

• 主要7市場における中等度から重度のアトピー性皮膚炎の市場規模は、2023年に約104億米ドルであり、予測期間に大幅なCAGRで増加すると予測されます。
• 主要7市場で中等度から重度のアトピー性皮膚炎の市場規模がもっとも大きいのは米国であり、2023年に市場全体の約7,100米ドルを占めました。
• 主要7市場のアトピー性皮膚炎の総患者数は、2023年に最大7,270万7,300人でした。
• 現在、アトピー性皮膚炎の治療法としては、エモリエント剤、局所副腎皮質ステロイド（TCS）、局所カルシニューリン阻害薬（TCI）などの外用療法、免疫抑制剤、副腎皮質ステロイドなどの全身療法（光線療法）が行われています。中等度から重度の症例では、特に難治性の症例や体表面積に病変があり外用が実用的でない症例では、全身療法が正当化されます。
• 2017年のDUPIXENT（dupilumab）の承認は、アトピー性皮膚炎患者の治療情勢に画期的な変化をもたらしました。この薬剤は、成人（2017年）、12～17歳の青年（2019年）、6～11歳の小児（2020年）、6ヶ月～5歳の小児（2022年）と、さまざまな年齢層にわたる中等度から重度のアトピー性皮膚炎に対してFDAから順次承認されており、特に外用療法でコントロールが不十分な患者や外用療法が適さない患者を対象としています。
• 中等度から重度のアトピー性皮膚炎を有する成人と青少年の治療薬としてFDAに承認されている他の治療薬には、EBGLYSS（lebrikizumab）、RINVOQ（upadacitinib）、CIBINQO（abrocitinib）、ADBRY（tralokinumab）、OLUMIANT（baricitinib）などがあります。これら以外では、VTAMA（tapinarof）、MITCHGA（nemolizumab）、MOIZERTO（difamilast）、コレクチム軟膏（delgocitinib）などが日本でのみ承認されています。
• アトピー性皮膚炎に対する新たな生物学的療法は、IL-4、IL-13、IL-22、IL-31、TSLP、OX40-OX40L軸など、アトピー性皮膚炎の病態生理に不可欠な特定の免疫学的経路に焦点を当てるようになってきています。これらの生物学的製剤の臨床試験が進むにつれて、アトピー性皮膚炎の治療情勢を再構築する可能性があります。
• 中等度から重度のアトピー性皮膚炎の治療薬を開発している製薬企業には、Kyowa KirinとAmgen（Rocatinlimab）、Kymab/Sanofi（Amlitelimab）、UNION Therapeutics（Orismilast）、Biosion（Bosakitug）、LEO Pharma（Temtokibart）、Connect Biopharma（Rademikibart）、Aclaris Therapeutics（ATI-1777）、GSK（GSK1070806）、Nektar Therapeutics（Rezpegaldesleukin）、Apogee Therapeutics（APG777）などがあります。
• アトピー性皮膚炎では、より簡便な投与レジメンへの需要が高まっており、APG777のように年1回の投与が可能な治療薬が、現在隔週から月1回の投与が主流となっている市場を破壊する見通しです。さらに、ATI-1777、orismilast、tradipitantなどの外用薬や経口薬の開発は、注射針を嫌う患者に効果的な選択肢を提供しています。これらの進歩は患者のアドヒアランスを高め、頻繁な投与を必要とする注射用生物学的製剤の優位性に挑戦すると予測されています。
• 若年層におけるアトピー性皮膚炎の罹患率の上昇や、小児患者向けに承認された治療薬が限られていることから、小児や青少年向けに特別にデザインされた治療薬、特に長期的な安全性を重視した生物学的製剤を開発する大きな機会となっています。
• 世界市場の拡大に後押しされたアトピー性皮膚炎治療の進化する情勢は、アトピー性皮膚炎の転帰を再定義し、重大なギャップに対処して生存率を向上させる可能性を秘めています。

当レポートでは、重症アトピー性皮膚炎の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 エグゼクティブサマリー

第4章 中等度から重度のアトピー性皮膚炎市場の概要

• 主要7市場における市場シェアの分布：治療法別（2020年）
• 主要7市場における市場シェアの分布：治療法別（2034年）

第5章 疫学と市場調査手法

第6章 主な出来事

第7章 疾患の背景と概要

• 兆候と症状
• 原因ときっかけ
• 臨床症状
• 病態生理学
• バイオマーカー
• 診断
  • アトピー性皮膚炎の診断基準
  • 鑑別診断

第8章 治療と管理

• 治療アルゴリズム

第9章 ガイドライン

• ATOPIC DERMATITIS（ECZEMA）GUIDELINES：AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY/AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY JOINT TASK FORCE ON PRACTICE PARAMETERS GRADE AND INSTITUTE OF MEDICINE（2023年）
• JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY：GUIDELINES OF CARE FOR THE MANAGEMENT OF ATOPIC DERMATITIS IN ADULTS WITH TOPICAL THERAPIES（2024年）
• ATOPIC DERMATITIS CLINICAL GUIDELINE：AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION（2014年）
• S2K GUIDELINES ON DIAGNOSIS AND TREATMENT OF ATOPIC DERMATITIS（2016年）
• UPDATED S2K-GUIDELINS FOR THE SYSTEMIC TREATMENT OF ATOPIC DERMATITIS（2021年）
• S3 GUIDELINES ATOPIC DERMATITIS：PART 1 - GENERAL ASPECTS, TOPICAL AND NON-DRUG THERAPIES, SPECIAL PATIENT GROUPS（2024年）
• S3 GUIDELINE ATOPIC DERMATITIS：PART 2 - SYSTEMIC TREATMENT（2024年）
• ATOPIC ECZEMA IN UNDER 12S：DIAGNOSIS AND MANAGEMENT BY NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE（NICE）（2020年）
• ATOPIC ECZEMA IN UNDER 12S：DIAGNOSIS AND MANAGEMENT（2023年更新）
• EUROPEAN GUIDELINES（EUROGUIDERM）ON ATOPIC ECZEMA：PART I - SYSTEMIC THERAPY（2022年）
• EUROPEAN GUIDELINES（EUROGUIDERM）ON ATOPIC ECZEMA：PART II（2022年）

第10章 疫学と患者人口

• 主な調査結果
• 主要7市場のアトピー性皮膚炎の総患者数
• 前提条件と根拠
• 米国
• 欧州4ヶ国・英国
• 日本

第11章 ペイシェントジャーニー

第12章 上市済み薬品

• 主な競合相手
• ADBRY/ADTRALZA（TRALOKINUMAB）：LEO PHARMA
  • 製品の説明
  • 規制のマイルストーン
  • その他の開発活動
  • 臨床開発
  • 安全性と有効性
• EBGLYSS（LEBRIKIZUMAB）：ROCHE/ELI LILLY、COMPANY/ALMIRALL
• VTAMA（TAPINAROF）：ORGANON/TORII PHARMACEUTICAL
• MITCHGA（NEMOLIZUMAB）：CHUGAI PHARMACEUTICAL/GALDERMA/MARUHO
• RINVOQ（UPADACITINIB）：ABBVIE
• CIBINQO（ABROCITINIB）：PFIZER
• DUPIXENT（DUPILUMAB）：SANOFI、REGENERON PHARMACEUTICALS
• OLUMIANT（BARICITINIB; LY3009104）：ELI LILLY、COMPANY、INCYTE
• CORECTIM OINTMENT（DELGOCITINIB）：JAPAN TOBACCO/LEO PHARMA/TORII PHARMACEUTICAL
• MOIZERTO（DIFAMILAST）：OTSUKA PHARMACEUTICAL/MEDIMETRIKS PHARMACEUTICALS/ACROTECH BIOPHARMA

第13章 新薬

• 主な競合相手
• ROCATINLIMAB（KHK4083/AMG451）：KYOWA KIRIN、AMGEN
  • 製品の説明
  • その他の開発活動
  • 臨床開発
  • 安全性と有効性
• AMLITELIMAB（KY1005）：KYMAB/SANOFI
• ORISMILAST：UNION THERAPEUTICS
• BOSAKITUG（BSI-045B）：BIOSION、ACLARIS THERAPEUTICS
• TEMTOKIBART（LP0145; LEO 138559）：LEO PHARMA
• RADEMIKIBART（CBP-201）：CONNECT BIOPHARMA
• LEPZACITINIB（ATI-1777）：ACLARIS THERAPEUTICS
• その他の新薬の安全性と有効性に関するデータ

第14章 中等度から重度のアトピー性皮膚炎：主要7市場の分析

• 主な調査結果
• 市場見通し
• コンジョイント分析
• 主な市場予測の前提条件
• 主要7市場の中等度から重度のアトピー性皮膚炎の総市場規模
• 米国の市場規模
  • 米国の中等度から重度のアトピー性皮膚炎の総市場規模
  • 米国の中等度から重度のアトピー性皮膚炎の市場規模：治療法別
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国の中等度から重度のアトピー性皮膚炎の総市場規模
  • 欧州4ヶ国・英国の中等度から重度のアトピー性皮膚炎の市場規模：治療法別
• 日本
  • 日本の中等度から重度のアトピー性皮膚炎の総市場規模
  • 日本の中等度から重度のアトピー性皮膚炎の市場規模：治療法別

第15章 アンメットニーズ

第16章 SWOT分析

第17章 KOLの見解

第18章 市場参入と償還

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本
• アトピー性皮膚炎の償還

第19章 付録

第20章 DelveInsightの機能

第21章 免責事項

第22章 DelveInsightについて

List of Tables

• Table 1: Summary of Moderate-to-severe Atopic Dermatitis Market and Epidemiology (2020-2034)
• Table 2: Atopic Dermatitis Diagnostic Criteria as Defined by Hanifin and Rajka and as Subsequently Adapted by the UK Working Party
• Table 3: Differential Diagnosis of Atopic Dermatitis
• Table 4: Topical Corticosteroids Ranked by Potency (from Most Potent to Least Potent)
• Table 5: Recommendations for the Management of Atopic Dermatitis in Adults with Phototherapy and Systemic Therapies
• Table 6: Features to be Considered in the Diagnosis of Patients With Atopic Dermatitis
• Table 7: Dosing and Monitoring Guidelines for the use of Selected Systemic Agents
• Table 8: Stepped Treatment Options (NICE)
• Table 9: Total Prevalent Cases of Atopic Dermatitis in the 7MM, in Thousand (2020-2034)
• Table 10: Total Prevalent Cases of Atopic Dermatitis in the US, in Thousand (2020-2034)
• Table 11: Total Prevalent Cases of Atopic Dermatitis by Age in the US, in Thousand (2020-2034)
• Table 12: Total Diagnosed Cases of Atopic Dermatitis in the US, in Thousand (2020-2034)
• Table 13: Total Diagnosed Cases of Atopic Dermatitis by Severity in the US, in Thousand (2020-2034)
• Table 14: Total Diagnosed Cases of Atopic Dermatitis by Gender in the US, in Thousand (2020-2034)
• Table 15: Total Prevalent Cases of Atopic Dermatitis in EU4 and the UK, in Thousand (2020-2034)
• Table 16: Total Prevalent Cases of Atopic Dermatitis by Age in EU4 and the UK, in Thousand (2020-2034)
• Table 17: Total Diagnosed Prevalent Cases of Atopic Dermatitis in the EU4 and the UK, in Thousand (2020-2034)
• Table 18: Total Diagnosed Cases of Atopic Dermatitis by Severity in EU4 and the UK, in Thousand (2020-2034)
• Table 19: Total Diagnosed Cases of Atopic Dermatitis by Gender in EU4 and the UK, in Thousand (2020-2034)
• Table 20: Total Prevalent Cases of Atopic Dermatitis in Japan, in Thousand (2020-2034)
• Table 21: Total Prevalent Cases of Atopic Dermatitis by Age in Japan, in Thousand (2020-2034)
• Table 22: Total Diagnosed Cases of Atopic Dermatitis in Japan, in Thousand (2020-2034)
• Table 23: Total Diagnosed Cases of Atopic Dermatitis by Severity in Japan, in Thousand (2020-2034)
• Table 24: Total Diagnosed Cases of Atopic Dermatitis by Gender in Japan, in Thousand (2020-2034)
• Table 25: Comparison of Marketed Drugs
• Table 26: ADBRY Dosage in Adults
• Table 27: ADBRY Dosage in Pediatric Patients 12 Years of Age and Older
• Table 28: ADBRY/ADTRALZA (Tralokinumab), Clinical Trial Description, 2024
• Table 29: EBGLYSS (Lebrikizumab [LY3650150]), Clinical Trial Description, 2024
• Table 30: MITCHGA (nemolizumab), Clinical Trial Description, 2024
• Table 31: Patents
• Table 32: RINVOQ (upadacitinib), Clinical Trial Description, 2024
• Table 33: Patent Information of CIBINQO (Abrocitinib)
• Table 34: CIBINQO (abrocitinib), Clinical Trial Description, 2024
• Table 35: Dosage of DUPIXENT in pediatric patients 6 months to 5 years of age
• Table 36: Dosage of DUPIXENT in Pediatric Patients 6-17 Years of age
• Table 37: Patent Information of DUPIXENT
• Table 38: DUPIXENT (dupilumab), Clinical Trial Description, 2024
• Table 39: Comparison of Emerging Drugs Under Development
• Table 40: Rocatinlimab (KHK4083/AMG451), Clinical Trial Description, 2024
• Table 41: Amlitelimab (KY1005), Clinical Trial Description, 2024
• Table 42: Orismilast, Clinical Trial Description, 2024
• Table 43: Bosakitug (BSI-045B), Clinical Trial Description, 2024
• Table 44: Temtokibart (LP0145; LEO 138559), Clinical Trial Description, 2024
• Table 45: Rademikibart (CBP-201), Clinical Trial Description, 2024
• Table 46: Lepzacitinib (ATI-1777), Clinical Trial Description, 2024
• Table 47: Comparison of Safety and Efficacy of Emerging Drugs
• Table 48: Key Market Forecast Assumption of Moderate to Severe Atopic Dermatitis in the US
• Table 49: Key Market Forecast Assumption of Moderate to Severe Atopic Dermatitis in EU4 and the UK
• Table 50: Key Market Forecast Assumption of Moderate to Severe Atopic Dermatitis in Japan
• Table 51: Total Market Size of Moderate-to-severe Atopic Dermatitis in the 7MM, USD million (2020-2034)
• Table 52: Total Market Size of Moderate-to-severe Atopic Dermatitis in the US, USD million (2020-2034)
• Table 53: Market Size of Moderate-to-severe Atopic Dermatitis by Therapies in the US, USD million (2020-2034)
• Table 54: Total Market Size of Moderate-to-severe Atopic Dermatitis in EU4 and the UK, USD million (2020-2034)
• Table 55: Total Market Size of Moderate-to-severe Atopic Dermatitis by Therapies in EU4 and the UK, USD million (2020-2034)
• Table 56: Total Market Size of Moderate-to-severe Atopic Dermatitis in the Japan, USD million (2020-2034)
• Table 57: Market Size of Moderate-to-severe Atopic Dermatitis by Therapies in Japan, USD million (2020-2034)
• Table 58: NICE Assessment for Therapies in Atopic Dermatitis
• Table 59: G-BA Benefit Assessment for Therapies in Neuroendocrine Tumor
• Table 60: HAS Opinions for Therapies in Atopic Dermatitis
• Table 61: AIFA Assessment for Therapies in Atopic Dermatitis
• Table 62: AEMPS Assessment for Therapies in Atopic Dermatitis

List of Figures

• Figure 1: Algorithm for the treatment of Atopic Dermatitis
• Figure 2: Medical Algorithm for the Therapeutic Management of Atopic Dermatitis in Early Childhood, Based on the Severity
• Figure 3: Total Prevalent Cases of Atopic Dermatitis in the 7MM (2020-2034)
• Figure 4: Total Prevalent Cases of Atopic Dermatitis in the US (2020-2034)
• Figure 5: Total Prevalent Cases of Atopic Dermatitis by Age in the US (2020-2034)
• Figure 6: Total Diagnosed Prevalent Cases of AD in the US (2020-2034)
• Figure 7: Total Diagnosed Cases of Atopic Dermatitis by Severity in the US (2020-2034)
• Figure 8: Total Diagnosed Cases of Atopic Dermatitis by Gender in the US (2020-2034)
• Figure 9: Total Prevalent Cases of Atopic Dermatitis in EU4 and the UK (2020-2034)
• Figure 10: Total Prevalent Cases of Atopic Dermatitis by Age in EU4 and the UK (2020-2034)
• Figure 11: Total Diagnosed Prevalent Cases of Atopic Dermatitis in EU4 and the UK (2020-2034)
• Figure 12: Total Diagnosed Cases of Atopic Dermatitis by Severity in EU4 and the UK (2020-2034)
• Figure 13: Total Diagnosed Cases of Atopic Dermatitis by Gender in EU4 and the UK (2020-2034)
• Figure 14: Total Prevalent Cases of Atopic Dermatitis in Japan (2020-2034)
• Figure 15: Total Prevalent Cases of Atopic Dermatitis by Age in Japan (2020-2034)
• Figure 16: Total Diagnosed Prevalent Cases of Atopic Dermatitis in Japan (2020-2034)
• Figure 17: Total Diagnosed Cases of Atopic Dermatitis by Severity in Japan (2020-2034)
• Figure 18: Total Diagnosed Cases of Atopic Dermatitis by Gender in Japan (2020-2034)
• Figure 19: Total Market Size of Moderate-to-severe Atopic Dermatitis in the 7MM, USD million (2020-2034)
• Figure 20: Total Market Size of Moderate-to-severe Atopic Dermatitis in the US, USD million (2020-2034)
• Figure 21: Market Size of Moderate-to-severe Atopic Dermatitis by Therapies in the US, USD million (2020-2034)
• Figure 22: Total Market Size of Moderate-to-severe Atopic Dermatitis in EU4 and the UK, USD million (2020-2034)
• Figure 23: Market Size of Moderate-to-severe Atopic Dermatitis by Therapies in EU4 and the UK, USD million (2020-2034)
• Figure 24: Market Size of Moderate-to-severe Atopic Dermatitis in Japan, USD million (2020-2034)
• Figure 25: Market Size of Moderate-to-severe Atopic Dermatitis by Therapies in Japan, USD million (2020-2034)
• Figure 26: Health Technology Assessment
• Figure 27: Reimbursement Process in Germany
• Figure 28: Reimbursement Process in France
• Figure 29: Reimbursement Process in Italy
• Figure 30: Reimbursement Process in Spain
• Figure 31: Reimbursement Process in the United Kingdom
• Figure 32: Reimbursement Process in Japan

Key Highlights:

• The market size of moderate-to-severe atopic dermatitis in the 7MM was around USD 10,400 million in 2023 and is expected to increase with a significant CAGR during the forecast period.
• Among the 7MM, the US accounted for the largest market size of moderate-to-severe atopic dermatitis, i.e., approximately USD 7,100 of the overall market in 2023.
• The total prevalent cases of atopic dermatitis in the 7MM were ~ 72,707,300 in 2023.
• Currently, the treatment regimen of atopic dermatitis involves the use of topical treatment options such as emollients, Topical Corticosteroids (TCS), Topical Calcineurin Inhibitors (TCIs), and systemic treatment such as immunosuppressants, corticosteroids, and others (phototherapy). For moderate-to-severe disease, systemic therapies are warranted, particularly in refractory cases or in cases with body surface area involvement that makes topical application impractical.
• The approval of DUPIXENT (dupilumab) in 2017 marked a landmark change in the treatment landscape for atopic dermatitis patients. The drug has been progressively approved by the FDA for moderate-to-severe atopic dermatitis across various age groups: adults (2017), adolescents aged 12-17 (2019), children aged 6-11 (2020), and children aged 6 months-5 years (2022), specifically for patients inadequately controlled by or unsuitable for topical therapies.
• Other FDA-approved therapies for treating adults and adolescents with moderate-to-severe atopic dermatitis include EBGLYSS (lebrikizumab), RINVOQ (upadacitinib), CIBINQO (abrocitinib), ADBRY (tralokinumab), and OLUMIANT (baricitinib). Other than these, therapies such as VTAMA (tapinarof), MITCHGA (nemolizumab), MOIZERTO (difamilast), and CORECTIM ointment (delgocitinib) are only approved in Japan.
• Emerging biological therapies for atopic dermatitis are increasingly focusing on specific immune pathways such as IL-4, IL-13, IL-22, IL-31, TSLP, and OX40-OX40L axis, which are integral to the pathophysiology of the disease. As these biologics advance through clinical trials, they hold the potential to reshape the therapeutic landscape of atopic dermatitis.
• Pharmaceutical companies developing therapies for treating moderate-to-severe atopic dermatitis include Kyowa Kirin and Amgen (Rocatinlimab), Kymab/Sanofi (Amlitelimab), UNION Therapeutics (Orismilast), Biosion (Bosakitug), LEO Pharma (Temtokibart), Connect Biopharma (Rademikibart), Aclaris Therapeutics (ATI-1777), GSK (GSK1070806), Nektar Therapeutics (Rezpegaldesleukin), Apogee Therapeutics (APG777), and others.
• The demand for more convenient dosing regimens in atopic dermatitis is on the rise, with therapies like APG777, which offers the potential for annual dosing, poised to disrupt a market currently dominated by bi-weekly to monthly treatments. Additionally, the development of topical and oral options such as ATI-1777, orismilast, tradipitant, and others is providing needle-averse patients with effective alternatives. These advancements are expected to enhance patient adherence and challenge the dominance of injectable biologics requiring frequent administration.
• The rising incidence of atopic dermatitis in younger populations, combined with the limited availability of approved therapies for pediatric patients, presents a substantial opportunity to develop treatments specifically designed for children and adolescents, particularly long-term safety-focused biologics.
• The evolving landscape of atopic dermatitis therapies, bolstered by global market expansion, holds the potential to redefine outcomes in atopic dermatitis, addressing critical gaps and improving survival rates.

DelveInsight's "Severe Atopic Dermatitis - Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of moderate-to-severe atopic dermatitis, historical and forecasted epidemiology as well as the moderate-to-severe atopic dermatitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The moderate-to-severe atopic dermatitis market report provides current treatment practices, emerging drugs, moderate-to-severe atopic dermatitis market share of individual therapies, and current and forecasted moderate-to-severe atopic dermatitis market size from 2020 to 2034, segmented by seven major markets. The report also covers current moderate-to-severe atopic dermatitis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Moderate-to-Severe Atopic Dermatitis Disease Understanding and Treatment Algorithm

Moderate-to-severe Atopic Dermatitis Overview

Moderate-to-severe atopic dermatitis is a chronic inflammatory skin condition characterized by intense itching, red and inflamed lesions, and significant dryness, often leading to lichenification from chronic scratching. It primarily affects children but can persist into adulthood, impacting the quality of life through sleep disturbances and social withdrawal. The condition is associated with genetic predispositions, immune dysregulation, and environmental triggers, and it is part of the "atopic march," which can lead to other allergic diseases like asthma and allergic rhinitis. Patients frequently experience a range of symptoms that can vary in severity, and while some may see improvement over time, many continue to deal with the challenges posed by this persistent condition.

Moderate-to-severe Atopic Dermatitis Diagnosis

Currently, no specific test for atopic dermatitis exists, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of atopic dermatitis is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.

Atopic Dermatitis Treatment

Currently, the treatment regimen of atopic dermatitis involves the use of topical treatment options such as emollients, TCS, TCIs, and systemic treatment such as immunosuppressant, corticosteroids, and others (phototherapy).

Moderate-to-severe Atopic Dermatitis Epidemiology

The moderate-to-severe atopic dermatitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total prevalent cases of atopic dermatitis, total prevalent cases of atopic dermatitis by age, total diagnosed cases of atopic dermatitis, total diagnosed cases of atopic dermatitis by severity, total diagnosed cases of atopic dermatitis by gender, and total treated cases of atopic dermatitis in the 7MM covering the US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2020 to 2034.

• Among the 7MM, the US accounted for approximately 32,759,600 prevalent cases of atopic dermatitis in 2023.
• The US accounted for approximately 9,933,500, cases of moderate to severe atopic dermatitis in 2023.
• In the EU4 and the UK, in 2023, the total prevalent cases of atopic dermatitis by age were 9,202,300 (for patients >18 years) and 21,332,100 (For patients 18 years and above), which is expected to increase by 2034.
• As per the DelveInsight estimates, it has been found that the total diagnosed cases of atopic dermatitis by severity were 30,896,000 for mild, 19,289,700 for moderate, and 3,339,900 for severe atopic dermatitis in 7MM in 2023.

Atopic Dermatitis Drug Chapters

Marketed Drugs

EBGLYSS (lebrikizumab [LY3650150]): Roche/Eli Lilly and Company/Almirall

EBGLYSS is a monoclonal antibody that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate. EBGLYSS binds to the IL-13 cytokine at an area that overlaps with the binding site of the IL-4Ra subunit of the IL-13Ra1/IL-4Ra heterodimer, preventing the formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is implicated as a primary cytokine tied to the pathophysiology of eczema, driving the type-2 inflammatory loop in the skin, and EBGLYSS selectively targets IL-13

In September 2024, Eli Lilly and Company announced that the US FDA approved EBGLYSS (lebrikizumab-lbkz) for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies. In November 2023, Almirall announced that the EC had approved EBGLYSS (lebrikizumab-lbkz) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy. In January 2024, EBGLYSS (lebrikizumab-lbkz) was approved by MHLW for atopic dermatitis not responding adequately to conventional treatments with usual dosage for patients for adults and children aged =12 years weighing =40 kg is 500 mg of lebrikizumab (genetical recombination) at Week 0 and Week 2, followed by 250 mg at 2-week intervals after Week 4, administered by subcutaneous injection.

ADBRY/ADTRALZA (tralokinumab): LEO Pharma

ADBRY (tralokinumab) is marketed outside of the US under the tradename ADTRALZA and is approved for the treatment of adults and pediatric patients (12 years and above) with moderate-to-severe atopic dermatitis in the US, Canada, the European Union, the United Arab Emirates, Great Britain, and South Korea. ADTRALZA is approved for use in adults with moderate-to-severe atopic dermatitis in Saudi Arabia, Switzerland, and Japan. ADBRY is the first biological injection that specifically targets IL-13, one of the proteins in the immune system that contributes to skin inflammation in eczema. ADBRY is an antibody that works with the immune system to neutralize IL-13, helping prevent inflammation in your skin. It is a drug for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

In December 2021, LEO Pharma announced that the US FDA had approved ADBRY for treating moderate-to-severe atopic dermatitis in adults aged 18 or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In June 2021, LEO Pharma announced that the European Commission (EC) approved ADTRALZA or the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. In December 2022, LEO Pharma announced that the Japan Ministry of Health, Labor and Welfare (MHLW) approved the manufacturing and marketing of ADTRALZA subcutaneous injection for adults with atopic dermatitis, which has inadequately responded to conventional therapies.

Emerging Drugs

Rocatinlimab (KHK4083/AMG451): Kyowa Kirin and Amgen

Rocatinlimab is an anti-OX40 human monoclonal antibody being investigated for the treatment of moderate-to-severe atopic dermatitis. Rocatinlimab has the potential to be the first and only T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. OX40 is a co-stimulatory receptor responsible for driving systemic and local inflammatory responses in atopic dermatitis and other conditions. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with atopic dermatitis and are critical in the disease pathophysiology. It is also being studied for moderate to severe uncontrolled asthma, prurigo nodularis, and potentially other conditions where T-cell imbalance is a root cause of inflammation. The initial antibody was discovered in collaboration between Kyowa Kirin and La Jolla Institute for Immunology. Rocatinlimab is currently under clinical investigation, and the US FDA or any other regulatory authority has not evaluated its safety and efficacy.

As per Amgen's third quarter financial results for 2024, additional key data readouts from the ROCKET Phase III programs are anticipated in 2025, with ROCKET SHUTTLE anticipated in late 2024 to early 2025, ROCKET IGNITE anticipated in late 2024-early 2025, ROCKET ASCEND, data readout is anticipated in H2 2025. ROCKET ASTRO, data readout is anticipated in H2 2025.

Amlitelimab (KY1005): Kymab/Sanofi

Amlitelimab is a fully human non-T-cell depleting monoclonal antibody that blocks OX40-Ligand, a key immune regulator. It has the potential to be a first- or best-in-class treatment for a range of immune-mediated diseases and inflammatory disorders, including moderate-to-severe atopic dermatitis. In June 2023, the Phase IIb (STREAM-AD) results announced that the drug had its primary endpoint in adults with moderate-to-severe atopic dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical medications are not a recommended treatment approach.

As per the Q4 presentation of Sanofi in February 2024, the company anticipates the submission of amlitelimab (KY1005) for atopic dermatitis in adults and adolescents by 2027.

Drug Class Insight

IL-13 inhibitors

IL-13 inhibitors, such as EBGLYSS and ADBRY, play a crucial role in treating moderate to severe atopic dermatitis (AD) by selectively targeting and blocking the IL-13 cytokine, which is central to the inflammatory processes underlying the disease. These biologics have demonstrated significant efficacy in clinical trials, leading to rapid improvements in key symptoms like skin lesions, itching, and overall quality of life. Specifically, they reduce the expression of inflammatory markers and enhance skin barrier function, which is often compromised in AD patients. Both EBGLYSS and ADBRY have shown good safety profiles, with mild adverse effects, making them promising options for patients inadequately controlled by traditional therapies.

JAK inhibitors

JAK inhibitors, including CIBINQO and RINVO function by blocking the JAK enzymes involved in the JAK-STAT signaling pathway, which is crucial for mediating inflammatory responses in atopic dermatitis. By inhibiting JAK1, JAK2, and JAK3, these medications disrupt the signaling of various cytokines that contribute to inflammation and immune cell activation, leading to reduced production of pro-inflammatory cytokines such as IL-4, IL-13, and IL-31. This results in significant improvements in skin lesions, decreased itching, and enhanced skin barrier function. Clinical trials have demonstrated that both oral and topical JAK inhibitors can rapidly alleviate symptoms of moderate-to-severe atopic dermatitis, providing effective relief for patients who have not responded adequately to traditional therapies. Additionally, their favorable safety profiles make them a valuable option in managing this chronic condition.

Moderate-to-severe Market Outlook

The current market uses several off-label therapies apart from pharmacological systemic treatment. Localized atopic itch is frequently treated with topical or intralesional therapeutic agents. Topical corticosteroids have been used for AD for decades. Pimecrolimus and tacrolimus, topical calcineurin inhibitors, are used as steroid-sparing agents for patients with AD. Phosphodiesterase-4 (PDE-4) inhibitors are an alternative option for the topical treatment of pruritis in AD. Oral antihistamines are commonly used for atopic itch. Additionally, phototherapy is efficacious in targeting atopic itch.

The current treatment landscape for atopic dermatitis includes several medications across different regions, with the U.S. market featuring DUPIXENT, OPZELURA, RINVOQ, EUCRISA, CIBINQO, and ADBRY/ADTRALZA. EUCRISA, a phosphodiesterase 4 inhibitor approved in December 2016, is specifically indicated for mild to moderate AD in patients aged three months and older. OPZELURA (ruxolitinib) cream, a topical JAK inhibitor approved in September 2021, is the first JAK inhibitor available in the U.S., joining two other oral JAK inhibitors for AD treatment. In Europe (EU4) and the UK, the market includes DUPIXENT, RINVOQ, CIBINQO, and ADBRY/ADTRALZA, while STAQUIS received marketing authorization in March 2020 but was withdrawn in January 2022 for commercial reasons. Japan's market mirrors that of the U.S. and EU with products like DUPIXENT and CIBINQO approved for moderate to severe AD. The recent approvals of CIBINQO and ADTRALZA in Japan provide hope for improved treatment options in a country with limited therapies for this chronic condition.

Conclusively, while the treatment of atopic itch is challenging, advancements in the last several years have provided multiple options ranging from topical agents to systemic therapies. In addition, newer treatments on the horizon hold great promise. Moreover, improved treatment of atopic itch will improve AD symptoms and the quality of life in many patients across 7MM.

• Among the 7MM, the US accounted for the largest market size of moderate-to-severe atopic dermatitis, i.e., approximately USD 7,100 of the overall market in 2023.
• Among EU4, Germany accounted for the highest market size in 2023 (i.e. USD 560 million), while the Spain occupied the lowest (i.e. USD 360 million).
• In 2034, among all the therapies, the highest revenue was generated by DUPIXENT in the 7MM.

Key Updates

• In November 2024, Aclaris Therapeutics entered into an exclusive license agreement with Biosion for worldwide rights.
• In October 2024, LEO Pharma presented the final results of the five-year extension study ECZTEND of ADBRY in adults and adolescent patients (aged 12 years and over) with moderate-to-severe atopic dermatitis at the Fall Clinical Dermatology Conference.
• In September 2024, Kyowa Kirin announced the top-line data from the Phase III ROCKET HORIZON trial for adults with moderate-to-severe atopic dermatitis.
• In September 2024, the data from the EBGLYSS ADjoin long-term extension study was presented at the EADV Congress.
• In September 2024, Eli Lilly and Company announced that the US FDA approved EBGLYSS (lebrikizumab) for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies.
• In March 2024, Chugai Pharmaceutical announced that Maruho obtained regulatory approval from the MHLW for MITCHGA subcutaneous injection of 30 mg vials for the treatment of atopic dermatitis (children aged =6 and <13 years) in Japan.
• In February 2024, Galderma announced that the EMA accepted the MAA of MITCHGA for atopic dermatitis.

Moderate-to-severe Atopic Dermatitis Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2020-2034. The landscape of moderate-to-severe atopic dermatitis treatment has experienced a profound transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of physicians, oncology professionals, and the entire healthcare community in their tireless pursuit of advancing cancer care. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Moderate-to-severe Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, Phase I/II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for GBM emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, PhD, Research Project Manager, Director, and others. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or GBM market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Delveinsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the RWTH Aachen University Hospital, University of Valencia, Vall d'Hebron University Hospital, Drexel University, Saint Louis University, University of Birmingham, Juntendo University, Kyoto University, etc., were contacted. Their opinion helps understand and validate GBM epidemiology and market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial's primary and secondary outcome measures are evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Market Access and Reimbursement

DUPIXENT (dupilumab)

DUPIXENT MyWay: It is a patient support program that can help access DUPIXENT and offers financial assistance to eligible patients, one-on-one nursing support, and more. DUPIXENT MyWay can assist with:

• Verifying patient's specific health plan coverage for DUPIXENT
• Determining Utilization Management (UM) criteria
• Identifying patient's possible out-of-pocket responsibilities
• Helping navigate any required prior authorization (PA) processes
• Educating patients about the appeals process if coverage is denied

Copay card: Eligible patients covered by commercial health insurance may pay as little as a USD 0* copay per fill of DUPIXENT (maximum of USD 13,000 per patient per calendar year). Patients may be eligible for the DUPIXENT MyWay copay card if they:

• Have commercial insurance
• Have a DUPIXENT prescription for an FDA-approved condition
• Are a resident of the 50 United States, the District of Columbia, Puerto Rico, Guam, or the USVI, and are a patient or caregiver aged 18 years or older.
• Approval is not guaranteed. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed, or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use without notice.

Scope of the Report:

• The report covers a descriptive overview of moderate-to-severe atopic dermatitis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into moderate-to-severe atopic dermatitis epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for moderate-to-severe atopic dermatitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the moderate-to-severe atopic dermatitis market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM moderate-to-severe atopic dermatitis market.

Moderate-to-severe Atopic Dermatitis Report Insights

• Patient Population
• Therapeutic Approaches
• Moderate-to-severe Atopic Dermatitis Pipeline Analysis
• Moderate-to-severe atopic dermatitis Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Moderate-to-severe Atopic Dermatitis Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Moderate-to-severe Atopic Dermatitis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Moderate-to-severe Atopic Dermatitis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What was the moderate-to-severe atopic dermatitis market share (%) distribution in 2020 and what it would look like in 2034?
• What would be the moderate-to-severe atopic dermatitis total market size as well as market size by therapies across the 7MM during the study period (2020-2034)?
• Which country will have the largest moderate-to-severe atopic dermatitis market size during the study period (2020-2034)?
• What are the disease risks, burdens, and unmet needs of moderate-to-severe atopic dermatitis?
• What is the historical moderate-to-severe atopic dermatitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What will be the growth opportunities across the 7MM concerning the patient population of moderate-to-severe atopic dermatitis?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of moderate-to-severe atopic dermatitis?
• What are the key collaborations (Industry-Industry, Industry), mergers and acquisitions, and licensing activities related to moderate-to-severe atopic dermatitis therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the clinical studies going on for moderate-to-severe atopic dermatitis and their status?
• What are the key designations that have been granted for the emerging therapies for moderate-to-severe atopic dermatitis?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving moderate-to-severe atopic dermatitis.
• To understand the future market competition in the moderate-to-severe atopic dermatitis market and an insightful review of the SWOT analysis of moderate-to-severe atopic dermatitis.
• Organize sales and marketing efforts by identifying the best opportunities for moderate-to-severe atopic dermatitis in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the moderate-to-severe atopic dermatitis market.
• To understand the future market competition in the moderate-to-severe atopic dermatitis market.

Table of Contents

1. KEY INSIGHTS

2. REPORT INTRODUCTION

3. EXECUTIVE SUMMARY

4. MODERATE-TO-SEVERE ATOPIC DERMATITIS MARKET OVERVIEW AT A GLANCE

• 4.1. MARKET SHARE DISTRIBUTION BY THERAPIES (%) IN 2020 IN THE 7MM
• 4.2. MARKET SHARE DISTRIBUTION BY THERAPIES (%) IN 2034 IN THE 7MM

5. EPIDEMIOLOGY AND MARKET METHODOLOGY

6. KEY EVENTS

7. DISEASE BACKGROUND AND OVERVIEW

• 7.1. SIGNS AND SYMPTOMS
• 7.2. CAUSES AND TRIGGERS
• 7.3. CLINICAL PRESENTATION
• 7.4. PATHOPHYSIOLOGY
• 7.5. BIOMARKERS
• 7.6. DIAGNOSIS
  • 7.6.1. Diagnostic Criteria for Atopic Dermatitis
  • 7.6.2. Differential Diagnosis

8. TREATMENT AND MANAGEMENT

• 8.1. TREATMENT ALGORITHM

9. GUIDELINES

• 9.1. ATOPIC DERMATITIS (ECZEMA) GUIDELINES: AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY/AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY JOINT TASK FORCE ON PRACTICE PARAMETERS GRADE AND INSTITUTE OF MEDICINE (2023)
• 9.2. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY: GUIDELINES OF CARE FOR THE MANAGEMENT OF ATOPIC DERMATITIS IN ADULTS WITH TOPICAL THERAPIES (2024)
• 9.3. ATOPIC DERMATITIS CLINICAL GUIDELINE: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION (2014)
• 9.4. S2K GUIDELINES ON DIAGNOSIS AND TREATMENT OF ATOPIC DERMATITIS (2016)
• 9.5. UPDATED S2K-GUIDELINS FOR THE SYSTEMIC TREATMENT OF ATOPIC DERMATITIS (2021)
• 9.6. S3 GUIDELINES ATOPIC DERMATITIS: PART 1 - GENERAL ASPECTS, TOPICAL AND NON-DRUG THERAPIES, SPECIAL PATIENT GROUPS (2024)
• 9.7. S3 GUIDELINE ATOPIC DERMATITIS: PART 2 - SYSTEMIC TREATMENT (2024)
• 9.8. ATOPIC ECZEMA IN UNDER 12S: DIAGNOSIS AND MANAGEMENT BY NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) (2020)
• 9.9. ATOPIC ECZEMA IN UNDER 12S: DIAGNOSIS AND MANAGEMENT (UPDATES 2023)
• 9.1. EUROPEAN GUIDELINES (EUROGUIDERM) ON ATOPIC ECZEMA: PART I - SYSTEMIC THERAPY (2022)
• 9.11. EUROPEAN GUIDELINES (EUROGUIDERM) ON ATOPIC ECZEMA: PART II (2022)

10. EPIDEMIOLOGY AND PATIENT POPULATION

• 10.1. KEY FINDINGS
• 10.2. TOTAL PREVALENT CASES OF ATOPIC DERMATITIS IN THE 7MM
• 10.3. ASSUMPTIONS AND RATIONALE
• 10.4. THE UNITED STATES
  • 10.4.1. Total Prevalent Cases of Atopic Dermatitis in the US
  • 10.4.2. Total Prevalent Cases of Atopic Dermatitis by Age in the US
  • 10.4.3. Total Diagnosed Prevalent Cases of Atopic Dermatitis in the US
  • 10.4.4. Total Diagnosed Cases of Atopic Dermatitis by Severity in the US
  • 10.4.5. Total Diagnosed Cases of Atopic Dermatitis by Gender in the US
• 10.5. EU4 AND THE UK
  • 10.5.1. Total Prevalent Cases of Atopic Dermatitis in EU4 and the UK
  • 10.5.2. Total Prevalent Cases of Atopic Dermatitis by Age in EU4 and the UK
  • 10.5.3. Total Diagnosed Prevalent Cases of Atopic Dermatitis in EU4 and the UK
  • 10.5.4. Total Diagnosed Cases of Atopic Dermatitis by Severity in EU4 and the UK
  • 10.5.5. Total Diagnosed Cases of Atopic Dermatitis by Gender in EU4 and the UK
• 10.6. JAPAN
  • 10.6.1. Total Prevalent Cases of Atopic Dermatitis in Japan
  • 10.6.2. Total Prevalent Cases of Atopic Dermatitis by Age in Japan
  • 10.6.3. Total Diagnosed Prevalent Cases of Atopic Dermatitis in Japan
  • 10.6.4. Total Diagnosed Cases of Atopic Dermatitis by Severity in Japan
  • 10.6.5. Total Diagnosed Cases of Atopic Dermatitis by Gender in Japan

11. PATIENT JOURNEY

12. MARKETED DRUGS

• 12.1. KEY COMPETITORS
• 12.2. ADBRY/ADTRALZA (TRALOKINUMAB): LEO PHARMA
  • 12.2.1. Product Description
  • 12.2.2. Regulatory Milestones
  • 12.2.3. Other Developmental Activities
  • 12.2.4. Clinical Development
  • 12.2.5. Safety and Efficacy
• 12.3. EBGLYSS (LEBRIKIZUMAB): ROCHE/ELI LILLY AND COMPANY/ALMIRALL
  • 12.3.1. Product Description
  • 12.3.2. Regulatory Milestones
  • 12.3.3. Other Developmental Activities
  • 12.3.4. Clinical Development
  • 12.3.5. Safety and Efficacy
• 12.4. VTAMA (TAPINAROF): ORGANON/TORII PHARMACEUTICAL
  • 12.4.1. Product Description
  • 12.4.2. Regulatory Milestones
  • 12.4.3. Other Developmental Activities
  • 12.4.4. Safety and Efficacy
• 12.5. MITCHGA (NEMOLIZUMAB): CHUGAI PHARMACEUTICAL/ GALDERMA/MARUHO
  • 12.5.1. Product Description
  • 12.5.2. Regulatory Milestones
  • 12.5.3. Other Developmental Activities
  • 12.5.4. Clinical Development
  • 12.5.5. Safety and Efficacy
• 12.6. RINVOQ (UPADACITINIB): ABBVIE
  • 12.6.1. Product Description
  • 12.6.2. Regulatory Milestones
  • 12.6.3. Other Developmental Activities
  • 12.6.4. Clinical Development
  • 12.6.5. Safety and Efficacy
• 12.7. CIBINQO (ABROCITINIB): PFIZER
  • 12.7.1. Product Description
  • 12.7.2. Regulatory Milestones
  • 12.7.3. Other Developmental Activities
  • 12.7.4. Clinical Development
  • 12.7.5. Safety and Efficacy
• 12.8. DUPIXENT (DUPILUMAB): SANOFI AND REGENERON PHARMACEUTICALS
  • 12.8.1. Product Description
  • 12.8.2. Regulatory Milestones
  • 12.8.3. Other Developmental Activities
  • 12.8.4. Clinical Development
  • 12.8.5. Safety and Efficacy
• 12.9. OLUMIANT (BARICITINIB; LY3009104): ELI LILLY AND COMPANY AND INCYTE
  • 12.9.1. Product Description
  • 12.9.2. Regulatory Milestones
  • 12.9.3. Other Developmental Activities
  • 12.9.4. Safety and Efficacy
• 12.1. CORECTIM OINTMENT (DELGOCITINIB): JAPAN TOBACCO/LEO PHARMA/TORII PHARMACEUTICAL
  • 12.10.1. Product Description
  • 12.10.2. Regulatory Milestones
  • 12.10.3. Other Developmental Activities
  • 12.10.4. Safety and Efficacy
• 12.11. MOIZERTO (DIFAMILAST): OTSUKA PHARMACEUTICAL/ MEDIMETRIKS PHARMACEUTICALS/ACROTECH BIOPHARMA
  • 12.11.1. Product Description
  • 12.11.2. Regulatory Milestones
  • 12.11.3. Other Developmental Activities
  • 12.11.4. Safety and Efficacy

13. EMERGING DRUGS

• 13.1. KEY COMPETITORS
• 13.2. ROCATINLIMAB (KHK4083/AMG451): KYOWA KIRIN AND AMGEN
  • 13.2.1. Product Description
  • 13.2.2. Other Developmental activities
  • 13.2.3. Clinical Development
  • 13.2.4. Safety and Efficacy
• 13.3. AMLITELIMAB (KY1005): KYMAB/SANOFI
  • 13.3.1. Product Description
  • 13.3.2. Other Developmental activities
  • 13.3.3. Clinical Development
  • 13.3.4. Safety and Efficacy
• 13.4. ORISMILAST: UNION THERAPEUTICS
  • 13.4.1. Product Description
  • 13.4.2. Other Developmental Activities
  • 13.4.3. Clinical Development
  • 13.4.4. Safety and Efficacy
• 13.5. BOSAKITUG (BSI-045B): BIOSION AND ACLARIS THERAPEUTICS
  • 13.5.1. Product Description
  • 13.5.2. Other Developmental Activities
  • 13.5.3. Clinical Development
  • 13.5.4. Safety and Efficacy
• 13.6. TEMTOKIBART (LP0145; LEO 138559): LEO PHARMA
  • 13.6.1. Product Description
  • 13.6.2. Clinical Development
  • 13.6.3. Safety and Efficacy
• 13.7. RADEMIKIBART (CBP-201): CONNECT BIOPHARMA
  • 13.7.1. Product Description
  • 13.7.2. Clinical Development
  • 13.7.3. Safety and Efficacy
• 13.8. LEPZACITINIB (ATI-1777): ACLARIS THERAPEUTICS
  • 13.8.1. Product Description
  • 13.8.2. Other Developmental Activities
  • 13.8.3. Clinical Development
  • 13.8.4. Safety and Efficacy
• 13.9. SAFETY AND EFFICACY DATA OF OTHER EMERGING DRUGS

14. MODERATE-TO-SEVERE ATOPIC DERMATITIS: 7MM ANALYSIS

• 14.1. KEY FINDINGS
• 14.2. MARKET OUTLOOK
• 14.3. CONJOINT ANALYSIS
• 14.4. KEY MARKET FORECAST ASSUMPTIONS
• 14.5. TOTAL MARKET SIZE OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN THE 7MM
• 14.6. UNITED STATES MARKET SIZE
  • 14.6.1. Total Market Size of Moderate-to-severe Atopic Dermatitis in the United States
  • 14.6.2. Market Size of Moderate-to-severe Atopic Dermatitis by Therapies in the United States
• 14.7. EU4 AND THE UK MARKET SIZE
  • 14.7.1. Total Market Size of Moderate-to-severe Atopic Dermatitis in EU4 and the UK
  • 14.7.2. Market Size of Moderate-to-severe Atopic Dermatitis by Therapies in EU4 and the UK
• 14.8. JAPAN
  • 14.8.1. Total Market size of Moderate-to-severe Atopic Dermatitis in Japan
  • 14.8.2. Market Size of Moderate-to-severe Atopic Dermatitis by Therapies in Japan

15. UNMET NEEDS

16. SWOT ANALYSIS

17. KOL VIEWS

18. MARKET ACCESS AND REIMBURSEMENT

• 18.1. UNITED STATES
  • 18.1.1. Centre for Medicare and Medicaid Services (CMS)
• 18.2. EU4 AND THE UK
  • 18.2.1. Germany
  • 18.2.2. France
  • 18.2.3. Italy
  • 18.2.4. Spain
  • 18.2.5. United Kingdom
• 18.3. JAPAN
  • 18.3.1. MHLW
• 18.4. REIMBURSEMENT OF ATOPIC DERMATITIS

19. APPENDIX

• 19.1. BIBLIOGRAPHY
• 19.2. REPORT METHODOLOGY

20. DELVEINSIGHT CAPABILITIES

21. DISCLAIMER

22. ABOUT DELVEINSIGHT